CLINICAL STUDIES
Creatine kinase-MB elevation after coronary intervention correlates with diffuse atherosclerosis, and low-to-medium level elevation has a benign clinical course
Implications for early discharge after coronary intervention
Annapoorna Kini, MDa,
Jonathan D. Marmur, MD, FACCa,
Subhash Kini, MDa,
George Dangas, MDa,
Thomas P. Cocke, MD, FACCa,
Sylvan Wallenstein, PhDa,
Eppie Brown, RNa,
John A. Ambrose, MD, FACCa and
Samin K. Sharma, MD, FACCa
a Cardiac Catheterization Laboratory of the Zena and Michael A. Weiner Cardiovascular Institute, Mount Sinai Hospital, New York, New York, USA
Manuscript received December 30, 1998;
revised manuscript received April 7, 1999,
accepted June 3, 1999.
Reprint requests and correspondence: Dr. Samin K. Sharma, Mount Sinai Hospital, Box 1030, One Gustave L. Levy Place, New York, New York 10029-6574 samin_sharma{at}smtplink.mssm.edu
OBJECTIVES
The study evaluated the incidence and predictors of creatine kinaseMB isoenzyme (CK-MB) elevation after successful coronary intervention using current devices, and assessed the influence on in-hospital course and midterm survival.
BACKGROUND
The CK-MB elevation after coronary intervention predominantly using balloon angioplasty correlates with late cardiac events of myocardial infarction (MI) and death. Whether CK-MB elevation after nonballoon devices is associated with an adverse short and midterm prognosis is unknown.
METHODS
The incidence and predictors of CK-MB elevation after coronary intervention were prospectively studied in 1,675 consecutive patients and were followed for in-hospital events and survival.
RESULTS
CK-MB elevation was detected in 313 patients (18.7%), with 13x in 12.8%, 35x in 3.5% and >5x normal in 2.4% of patients. Procedural complications or electrocardiogram changes occurred in only 49% of the CK-MB-elevation cases; CK-MB elevation was more common after nonballoon devices (19.5% vs. 11.5% after percutaneous transluminal coronary angioplasty; p < 0.01). Predictors of CK-MB elevation on multivariate analysis were diffuse coronary disease (p = 0.02), systemic atherosclerosis (p = 0.002), stent use (p = 0.04) and absence of beta-blocker therapy (p = 0.001). Adverse in-hospital cardiac events were more frequent in patients with >5x CK-MB elevation, with no significant difference between 15x CK-MB elevation versus normal CK-MB group. During a mean follow-up of 13 ± 3 months, the incidence of death in the CK-MB-elevation group was 1.6% versus 1.3% in the normal CK-MB group (p = NS).
CONCLUSIONS
The CK-MB elevation after coronary intervention was observed even in the absence of discernible procedural complications and was more common in patients with diffuse atherosclerosis. In-hospital clinical events requiring prolonged monitoring were higher in >5x CK-MB-elevation patients only. Midterm survival of CK-MB-elevation patients was similar to those with normal CK-MB. Our prospective analysis shows a lack of adverse in-hospital cardiac events and suggests that early discharge of stable 15x normal CK-MB-elevation patients after successful coronary intervention is safe.
|
Abbreviations and Acronyms
| | ACC/AHA | = American College of Cardiology/American Heart Association | | CABG | = coronary artery bypass grafting | | CCS | = Canadian Cardiovascular Society | | CHF | = congestive heart failure | | CK-MB | = creatine kinaseMB isoenzyme | | ECG | = electrocardiogram | | IAMP | = intra-aortic balloon pump | | LAD | = left anterior descending artery | | LVEF | = left ventricular ejection fraction | | MI | = myocardial infarction | | PRCA | = percutaneous rotational coronary atherectomy | | PTCA | = percutaneous transluminal coronary angioplasty | | RCA | = right coronary artery | | SVG | = saphenous vein graft | | TIMI | = thrombolysis in myocardial infarction | | TLR | = target lesion revascularization |
|
This article has been cited by other articles:

|
 |

|
 |
 
A. Prasad, B. J. Gersh, M. E. Bertrand, A. M. Lincoff, J. W. Moses, E. M. Ohman, H. D. White, S. J. Pocock, B. T. McLaurin, D. A. Cox, et al.
Prognostic significance of periprocedural versus spontaneously occurring myocardial infarction after percutaneous coronary intervention in patients with acute coronary syndromes: an analysis from the ACUITY (Acute Catheterization and Urgent Intervention Triage Strategy) trial.
J. Am. Coll. Cardiol.,
July 28, 2009;
54(5):
477 - 486.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
Y. J. Hong, G. S. Mintz, S. W. Kim, S. Y. Lee, T. Okabe, A. D. Pichard, L. F. Satler, R. Waksman, K. M. Kent, W. O. Suddath, et al.
Impact of Plaque Composition on Cardiac Troponin Elevation After Percutaneous Coronary Intervention: An Ultrasound Analysis
J. Am. Coll. Cardiol. Img.,
April 1, 2009;
2(4):
458 - 468.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. Prasad, C. S. Rihal, R. J. Lennon, M. Singh, A. S. Jaffe, and D. R. Holmes Jr
Significance of Periprocedural Myonecrosis on Outcomes After Percutaneous Coronary Intervention: An Analysis of Preintervention and Postintervention Troponin T Levels in 5487 Patients
Circ Cardiovasc Interv,
August 1, 2008;
1(1):
10 - 19.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
Y. J. Hong, M. H. Jeong, Y. Ahn, D. S. Sim, J. W. Chung, J. S. Cho, N. S. Yoon, H. J. Yoon, J. Y. Moon, K. H. Kim, et al.
Plaque prolapse after stent implantation in patients with acute myocardial infarction an intravascular ultrasound analysis.
J. Am. Coll. Cardiol. Img.,
July 1, 2008;
1(4):
489 - 497.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. Prasad, M. Singh, A. Lerman, R. J. Lennon, D. R. Holmes Jr, and C. S. Rihal
Isolated Elevation in Troponin T After Percutaneous Coronary Intervention Is Associated With Higher Long-Term Mortality
J. Am. Coll. Cardiol.,
November 7, 2006;
48(9):
1765 - 1770.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. Herrmann
Peri-procedural myocardial injury: 2005 update
Eur. Heart J.,
December 1, 2005;
26(23):
2493 - 2519.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
T Nageh, R A Sherwood, B M Harris, and M R Thomas
Prognostic role of cardiac troponin I after percutaneous coronary intervention in stable coronary disease
Heart,
September 1, 2005;
91(9):
1181 - 1185.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D. L. Bhatt and E. J. Topol
Periprocedural Cardiac Enzyme Elevation Predicts Adverse Outcomes
Circulation,
August 9, 2005;
112(6):
906 - 922.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D. E. Cutlip and R. E. Kuntz
Cardiac Enzyme Elevation After Successful Percutaneous Coronary Intervention Is Not an Independent Predictor of Adverse Outcomes
Circulation,
August 9, 2005;
112(6):
916 - 923.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. Cavallini, S. Savonitto, R. Violini, G. Arraiz, M. Plebani, Z. Olivari, P. Rubartelli, S. Battaglia, L. Niccoli, G. Steffenino, et al.
Impact of the elevation of biochemical markers of myocardial damage on long-term mortality after percutaneous coronary intervention: results of the CK-MB and PCI study
Eur. Heart J.,
August 1, 2005;
26(15):
1494 - 1498.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
W.-H. Chen, P.-Y. Lee, W. Ng, H.-F. Tse, and C.-P. Lau
Is aspirin resistance or female gender associated with a high incidence of myonecrosis after nonurgent percutaneous coronary intervention? Reply
J. Am. Coll. Cardiol.,
February 15, 2005;
45(4):
636 - 636.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. Briguori, A. Colombo, F. Airoldi, A. Violante, A. Focaccio, P. Balestrieri, P. Paolo Elia, B. Golia, S. Lepore, G. Riviezzo, et al.
Statin administration before percutaneous coronary intervention: impact on periprocedural myocardial infarction
Eur. Heart J.,
October 2, 2004;
25(20):
1822 - 1828.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
I. Iakovou, G. S. Mintz, G. Dangas, A. Abizaid, R. Mehran, Y. Kobayashi, A. J. Lansky, E. D. Aymong, E. Nikolsky, G. W. Stone, et al.
Increased CK-MB release is a "trade-off" for optimal stent implantation: an intravascular ultrasound study
J. Am. Coll. Cardiol.,
December 3, 2003;
42(11):
1900 - 1905.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D. O. Williams
A twist in our understanding of enzyme elevation after coronary intervention
J. Am. Coll. Cardiol.,
December 3, 2003;
42(11):
1906 - 1908.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
B. K. Nallamothu and E. R. Bates
Periprocedural myocardial infarction and mortality: Causality versus association
J. Am. Coll. Cardiol.,
October 15, 2003;
42(8):
1412 - 1414.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R. A. Henderson, S. J. Pocock, T. C. Clayton, R. Knight, K. A. A. Fox, D. G. Julian, D. A. Chamberlain, and Second Randomized Intervention Treatment of Angina
Seven-year outcome in the RITA-2 trial: coronary angioplasty versus medical therapy
J. Am. Coll. Cardiol.,
October 1, 2003;
42(7):
1161 - 1170.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. R. Kizer, M. R. Muttrej, W. H. Matthai, J. McConnell, H. Nardone, A. F. Sonel, M. G. Keane, and R. L. Wilensky
Role of cardiac troponin T in the long-term risk stratification of patients undergoing percutaneous coronary intervention
Eur. Heart J.,
July 2, 2003;
24(14):
1314 - 1322.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. S. Kini, P. Lee, C. A. Mitre, M. E. Duffy, and S. K. Sharma
Postprocedure chest pain after coronary stenting: implications on clinical restenosis
J. Am. Coll. Cardiol.,
January 1, 2003;
41(1):
33 - 38.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. G. Ellis, D. Chew, A. Chan, P. L. Whitlow, J. P. Schneider, and E. J. Topol
Death Following Creatine Kinase-MB Elevation After Coronary Intervention: Identification of an Early Risk Period: Importance of Creatine Kinase-MB Level, Completeness of Revascularization, Ventricular Function, and Probable Benefit of Statin Therapy
Circulation,
September 3, 2002;
106(10):
1205 - 1210.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J Herrmann, C von Birgelen, M Haude, L Volbracht, N Malyar, H Eggebrecht, T F M Konorza, D Baumgart, and R Erbel
Prognostic implication of cardiac troponin T increase following stent implantation
Heart,
June 1, 2002;
87(6):
549 - 553.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D. R. Holmes Jr and P. B. Berger
Troponisms, Necrosettes, Enzyme Leaks, Creatinine Phosphokinase Bumps, and Infarctlets: What's Behind This New Lexicon and What Does It Add?
Circulation,
August 7, 2001;
104(6):
627 - 629.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. S. Chauhan, R. E. Kuntz, K. K. L. Ho, D. J. Cohen, J. J. Popma, J. P. Carrozza Jr, D. S. Baim, and D. E. Cutlip
Coronary artery stenting in the aged
J. Am. Coll. Cardiol.,
March 1, 2001;
37(3):
856 - 862.
[Abstract]
[Full Text]
[PDF]
|
 |
|
|